To print: Select File and then Print from your browser's menu
---------------------------------------------------------------------------------------
Title: Higher Anaphylaxis Rates After HPV Vaccination in Australia
URL: http://www.pslgroup.com/dg/22A76A.htm
Doctor's Guide
September 2, 2008

OTTAWA, Ontario -- September 2, 2008 -- The estimated rate of anaphylaxis in young women after human papillomavirus (HPV) vaccination was 5 to 20 times higher than that identified in comparable school-based vaccination programs, according to a study published in the Canadian Medical Association Journal.

However, the overall rates of anaphylaxis were low with no associated serious lasting effects.

In a study of 114,000 women, a team of Australian researchers found 12 suspected cases of anaphylaxis, and confirmed 8 of these, in a 2007 vaccination program in New South Wales, Australia. Symptoms included difficulty breathing, nausea, and rashes.

Dr. Julia Brotherton, MD, National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Westmead, New South Wales, Australia, and colleagues postulate that reasons for an increased rate of anaphylaxis may include possible allergic reaction to the vaccine components, enhanced adverse event surveillance, higher rates of anaphylaxis in women from mid-adolescence compared with men, and an apparent increase in incidence of anaphylaxis in Australia.

The estimated rate of anaphylaxis following HPV vaccination was 2.6 per 100,000 doses administered compared with a rate 0.1 per 100 000 doses administered in a 2003 school-based meningococcal C vaccination program.

HPV vaccination programs will begin this fall in the United Kingdom and other European countries as well as in parts of Canada and the United States.

Dr. Brotherton stresses "the importance of good training for staff administering vaccines in school or other settings in the recognition and management of suspected anaphylaxis and its reporting." They conclude that anaphylaxis following the HPV vaccine is rare and vaccine programs should continue.

SOURCE: Canadian Medical Association Journal

---------------------------------------------------------------------------------------------
Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.
---------------------------------------------------------------------------------------------
This news story was printed from *Doctor's Guide to the Internet*
located at http://www.docguide.com
---------------------------------------------------------------------------------------

Return to News Story Page

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.
All contents Copyright (c) 1998 P\S\L Consulting Group Inc.
All rights reserved.